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Abstract
Background: Persistence on-treatment with antimuscarinics in patients with overactive bladder (OAB) is reported
to be sub-optimal. This retrospective, longitudinal, observational cohort study assessed treatment persistence with
β3-adrenoceptor agonists (i.e. mirabegron) and antimuscarinics, both classes of OAB pharmacotherapy, in patients
with OAB in Spain.
Methods: Adults who received mirabegron or an antimuscarinic in routine clinical practice (1 June–31 October
2014), were identified from anonymised prescription data within the Spanish Cegedim Electronic Medical Records
database. The primary endpoint, treatment persistence (time to treatment discontinuation [TTD] and the proportion
of patients remaining on-treatment after 12 months), was unadjusted for potential confounders. Multivariate Cox
regression models of persistence, adjusted for baseline characteristics, were used to compare differences in
treatment groups. Adjusted subgroup analyses (target OAB drug, age, treatment status and sex) and sensitivity
analyses (extending the time used to define treatment discontinuation from 30 days [base-case] to 45, 60 or
90 days without prescription renewal) were also performed.
Results: Overall, 1798 patients received mirabegron (N = 1169) or an antimuscarinic (N = 629); the mean age was 66.
42 years. Median TTD was longer for mirabegron versus antimuscarinics (90 vs 56 days) and a higher proportion of patients
who received mirabegron were persistent after 12 months (20.2% vs 10.2%); multivariate analyses indicated significantly
greater persistence with mirabegron versus antimuscarinics (hazard ratio [HR]: 1.52; 95% confidence interval [CI]: 1.37–1.70;
p < 0.001). Significant differences were also observed in subgroup analyses of mirabegron versus individual antimuscarinics
(median TTD: 90 vs [range] 28–60 days; HR range: 1.21–2.17; p ≤ 0.013) and in all other subgroups assessed (p < 0.001).
Sensitivity analysis showed that the median TTD for mirabegron increased by up to 31 days, and was significantly longer
versus antimuscarinics across all adjusted periods (HR range: 1.43–1.53; all p < 0.001).
Conclusions: Patients with OAB in Spain who received mirabegron experienced longer persistence on-treatment than
those who received antimuscarinics and the proportion of patients persistent on-treatment at 12 months with mirabegron
was two-times higher versus antimuscarinics. These data may provide strategic insights for clinicians and policy makers
involved in the management of OAB.
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Background
Overactive bladder (OAB) is characterised by urinary ur-
gency, usually accompanied by frequency and nocturia,
with or without urgency urinary incontinence, in the ab-
sence of urinary tract infection or other obvious pathology
[1, 2]. The prevalence of OAB in Spain is approximately
20% in patients ≥40 years of age; OAB is most common in
the elderly population, observed in more than one-quarter
of Spanish adults >70 years of age [3].
Health-related quality of life (HRQoL) is profoundly
affected in patients who experience OAB symptoms, as
demonstrated by clinically meaningful impairments in
HRQoL scores [4]. Aspects of life affected by OAB
symptoms include sexual health, personal relationships,
performing daily activities [5, 6], employment and prod-
uctivity in the workplace [6, 7]. The major impact of
symptoms is exemplified by a study of OAB in Spain,
which reported that 96% of patients adopted
non-medical coping strategies to help manage their daily
and occupational activities, and up to 10% of work time
was lost by patients experiencing urgency and urinary
incontinence (UI) [8]. OAB is also associated with a sub-
stantial economic burden; the total annual direct eco-
nomic impact (incremental costs) of OAB on the
Spanish National Healthcare System is estimated to be
around €366 million [7].
Following the use of conservative management strategies
(recommended as initial treatment for OAB), oral pharmaco-
therapy with β3−adrenoceptor agonists or antimuscarinic
agents can improve OAB symptoms [9]. However, evidence
from a large, retrospective analysis of medical and pharma-
ceutical claims database (N = 167,907) suggests that persist-
ence (i.e. the duration of time from initiation to
discontinuation of therapy [10]) and adherence (i.e. the ex-
tent to which a patient acts in accordance with the pre-
scribed interval, and dose of a dosing regimen [10]) to
antimuscarinics are low compared with pharmacological
therapies used to treat other chronic diseases, including sta-
tins and oral diabetics [11]. A systematic literature review
(SLR) and meta-analysis that assessed persistence and adher-
ence to antimuscarinic therapy for OAB (14 retrospective
database or self-report studies; N = 190,279) reported 12-
month median persistence rates of 12.0–39.4%; persistence
was evaluated up to 36 months and decreased over time
[12]. Data from a review of 14 retrospective medical claims
studies suggest that a high proportion (43–83%) of patients
with OAB discontinued antimuscarinic treatment within the
first 30 days [13]. In addition to poor tolerability, unmet
treatment expectations, patient education and costs are cited
as common reasons for discontinuing antimuscarinic
treatment [14].
Mirabegron is a first-in-class licensed, selective, oral β3
−adrenoceptor agonist, which was approved for the treat-
ment of OAB in Europe in December 2012 [15] and was
first marketed in Spain in April 2014 [16]. Improved effi-
cacy and similar tolerability for mirabegron compared
with placebo has been demonstrated in several phase III
studies [17–19]. Similar overall efficacy and improved
tolerability regarding bothersome anticholinergic adverse
events (AEs) was reported for mirabegron versus anti-
muscarinics in a network meta-analysis of 44 rando-
mised controlled trials of OAB (N = 27,309) [20].
Significant improvements in persistence and adherence
have been reported for mirabegron compared with anti-
muscarinics, in two large retrospective observational stud-
ies conducted in Canada and the United Kingdom (UK)
[21, 22]. Persistence was also significantly greater for mira-
begron versus tolterodine in a large, retrospective analysis
of claims records of patients in the United States [23].
These findings may be due, in part, to a lower incidence
of bothersome anticholinergic AEs, such as dry mouth, re-
ported for mirabegron compared with antimuscarinics
[20], which are frequent reasons for treatment discontinu-
ation [24–26]. Other factors such as the information pro-
vided for the patient about their condition (i.e. patient
education), patients’ willingness to take long-term treat-
ment, and treatment costs may also affect persistence and
adherence in patients with OAB [14, 27–29].
Persistence and adherence in patients with OAB are asso-
ciated with several clinical and economic benefits. Signifi-
cant improvements in OAB symptoms and HRQoL have
been reported in patients adherent to and those persistent
on-treatment, respectively, compared with non-adherent or
non-persistent patients [30, 31]. Moreover, economic
models of OAB suggest that improvements in persistence
with mirabegron versus antimuscarinics translate into re-
duced healthcare resource use, fewer lost work hours, and
lower total costs [32, 33].
Data are available from two retrospective, observa-
tional studies which evaluated treatment persistence and
adherence in patients receiving pharmacotherapy for
OAB in Spain [34, 35]. However, limitations in the de-
sign of these studies include possible under-reporting of
the incidence of OAB and a lack of evaluation of other
variables besides pharmacological treatment. Multivari-
ate analyses to adjust for the impact of baseline charac-
teristics were included in the current study, which
assessed treatment persistence and adherence observed
with mirabegron versus several common antimuscarinics
in patients with OAB in Spain.
Methods
Study design and objectives
This was a retrospective, longitudinal, observational co-
hort study of patients with OAB who received mirabe-
gron or an antimuscarinic drug in routine clinical
practice. Anonymised prescription records were col-
lected from the Spanish Cegedim Electronic Medical
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Records database, which holds information for approxi-
mately one million patients, submitted by primary and
secondary care physicians in Spain.
The primary objective was to compare treatment per-
sistence with mirabegron versus antimuscarinics in all
eligible patients with OAB. Secondary objectives in-
cluded: comparing treatment adherence with mirabe-
gron versus antimuscarinics in all eligible patients;
evaluating treatment persistence and adherence in differ-
ent subgroups; and investigating the impact of different
patient characteristics on treatment persistence and
adherence.
Ethics committee approval for the study was obtained
from the Hospital Clinic of Barcelona.
Study population
Eligible patients were ≥ 18 years of age and received a
prescription for a target OAB drug between 1 June and
31 October 2014 (i.e. the selection period); the date of
the first prescription of that drug was the index date
(Additional file 1: Figure S1). Eligible patients were also
required to have continuous enrolment during the pre-
and post-index periods (12 months prior to and
12 months after the index date, respectively). Exclusion
criteria were: prior prescription of the target OAB drug
or a 5α-reductase inhibitor during the pre-index period,
and prescription of another OAB drug (i.e. receipt of
concomitant therapy) at the index date or up to 30 days
afterwards; concomitant therapy was permitted > 30 days
after the index date. Eligible drugs were identified using
European Pharmaceutical Market Research Association
(EphMRA) Anatomical Therapeutic Chemical (ATC)
codes [36] (Additional file 2: Table S1).
Endpoints
Treatment persistence, the primary endpoint, was de-
fined as the time from the index date until first discon-
tinuation of the index drug (i.e. time to discontinuation
[TTD]). An index drug was considered discontinued
after a period of 30 days without prescription renewal.
Adherence, determined using the medical possession
ratio (MPR), was assessed as a secondary endpoint. This
was calculated by two methods: the sum of days’ supply
of the index drug, divided by 365 days (i.e. fixed-MPR),
or divided by the TTD (i.e. variable-MPR). Patients were
considered adherent with a MPR of ≥80%.
Statistical analyses
Treatment persistence and adherence (primary and sec-
ondary endpoints), assessed in all eligible patients, were
not adjusted for potential confounding factors and data
were reported descriptively. The unadjusted analyses of
persistence were presented using Kaplan-Meier curves
and reported as median TTD and the proportion of
patients persistent at the end of the 12-month
post-index period. The unadjusted analyses of adherence
were reported as mean MPR and the proportion of ad-
herent patients at the end of the 12-month post-index
period.
Multivariate analyses using Cox and linear regression
models were used to analyse TTD and MPR, respectively.
The target OAB drug (i.e. mirabegron or antimuscarinics)
was the independent variable; adjustments were made for
potential confounding baseline factors of treatment status
(naïve or experienced) and age (45–64, 65–74 or ≥ 75 years
for analyses of TTD; < 65 or ≥ 65 years for evaluation of
MPR). Treatment-naïve patients received no prescriptions
for an OAB drug during the 12 months prior to the index
date, while treatment-experienced patients received prior
prescription(s) for a different OAB drug to the index drug.
The models were fitted by including all covariates that
showed a significant relationship (p < 0.10) with TTD or
fixed- and variable-MPR in univariate Cox or linear re-
gression models. Additionally, a forward selection process
was used in the multivariate analyses and any variables
which did not maximise the quality of the models were
excluded [37, 38].
Analyses of treatment persistence and adherence for
mirabegron versus antimuscarinics (also using Cox and
linear regression models, respectively) were performed,
considering each individual antimuscarinic, and in the
following patient subgroups: treatment-naïve or -experi-
enced; < 65 or ≥ 65 years of age; and male or female. In
addition, sensitivity analyses were performed to assess
the impact of increasing the period without prescription
renewal used to define TTD from 30 days (base case) to
45, 60 and 90 days. The sensitivity analyses were also ad-
justed for baseline characteristics.
Adjusted analyses were reported as hazard ratios
(HRs) with 95% confidence intervals (CI) and p-values
for TTD, or p-values only for MPR. For all adjusted
comparisons, mirabegron was the reference comparator
and a p-value of < 0.05 was considered statistically
significant.
All analyses were performed using Statistical Analysis
Software, version 9.3.
Results
Baseline demographics and characteristics
Overall, 1975 patients received a prescription for a target
OAB drug during the selection period and 1798 were
eligible for inclusion (Fig. 1). The most common reasons
for exclusion were receipt of two or more different OAB
drugs (i.e. concomitant therapy) at index date or up to
30 days afterwards (N = 98), receipt of the index drug
during the pre-index period (N = 50), and < 18 years of
age at the index date (N = 36). A total of 1169 (65.0%)
eligible patients received mirabegron and 629 (35.0%)
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received an antimuscarinic. Solifenacin was the most
common prescribed antimuscarinic (N = 266; 14.8% of
patients).
The mean age at index date was 66.42 years (Table 1); a
higher proportion of patients were 65–80 years old in the
mirabegron arm compared with the antimuscarinic arm
(52.8% vs 44.0%), but a lower proportion were > 80 years
old (11.8% vs 18.6%). Overall, 1021 (56.8%) patients were
female; 637 (54.3%) and 384 (61.0%) in the mirabegron
and antimuscarinic arms, respectively. Body mass index
(BMI) data were available for 1185 patients, of whom, 545
(46.0%) were obese and 430 (36.3%) were overweight. Of
1289 (71.7%) treatment-naïve patients, a higher propor-
tion was observed in the antimuscarinic arm compared
with the mirabegron arm (85.7% vs 64.2%). Approximately
two-thirds of patients in the mirabegron arm received
their prescription in secondary care from a gynaecologist/
urologist; around three-quarters of patients treated with
an antimuscarinic received their prescription in primary
care, from a general practitioner (GP).
Persistence
All eligible patients
Median TTD was longer with mirabegron versus anti-
muscarinic therapy (90 vs 56 days, respectively (Fig. 2).
A higher proportion of patients prescribed mirabegron
were persistent at 12 months (N = 236; 20.2%) compared
with antimuscarinics (N = 64; 10.2%).
Multivariate analyses
Patients who received mirabegron were significantly less
likely to discontinue treatment compared with those pre-
scribed an antimuscarinic (HR: 1.52 [95% CI: 1.37–1.70];
p < 0.001) (Table 2). Patients < 75 years of age and
treatment-naïve patients were significantly more likely to
discontinue treatment compared with those ≥75 years of
age and treatment-experienced patients, respectively
(Table 2).
Subgroup analyses
Median TTD for mirabegron (90 days) was significantly
longer versus each individual antimuscarinic (range: 28–
60 days; HR range: 1.21–2.17; p ≤ 0.013), and a higher
proportion of patients were persistent at 12 months with
mirabegron (20.2%) versus individual antimuscarinics
(range: 3.2–13.9%) (Fig. 3). Among the antimuscarinics,
solifenacin had the longest median TTD and the highest
proportion of persistent patients. Treatment persistence
was significantly longer with mirabegron versus all anti-
muscarinics in all the other subgroups: treatment naïve
(HR: 1.47 [95% CI: 1.30–1.66]); treatment experienced
(HR: 1.80 [95% CI: 1.41–2.31]); < 65 years (HR: 1.39
[95% CI: 1.17–1.69]); ≥65 years (HR: 1.60 [95% CI: 1.39–
1.83]); male (HR: 1.75 [95% CI: 1.48–2.07]); and female
(HR: 1.37 [95% CI: 1.18–1.58]) (p < 0.001 for all compar-
isons) (Additional file 3: Figure S2).
Fig. 1 Patient selection flowchart.*Multiple reasons for exclusion may have applied for a single patient, therefore 202 reasons for exclusion are
listed; no patients were excluded because of an insufficient pre-index period (i.e. < 12 months’ history) or an insufficient post-index period (i.e. <
12 months’ follow-up); †Mirabegron or an antimuscarinic; eligible drugs listed in Additional file 6: Table S1. 5-ARI, 5α-reductase inhibitor; OAB,
overactive bladder
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Sensitivity analyses
Median TTD in patients prescribed mirabegron was in-
creased from 90 days in the base-case analysis to
121 days, when the period without prescription renewal
used to define treatment discontinuation was extended
from 30 to 90 days (Additional file 4: Figure S3). This
analysis had little impact on median TTD in patients
who received an antimuscarinic (range: 56–60 days
across all adjusted periods); median TTD was signifi-
cantly longer for mirabegron versus antimuscarinics
across all of the adjusted time periods used to define
treatment discontinuation (HR range: 1.43–1.53; p <
0.001 for all assessments).
Adherence
All eligible patients
Mean adherence using fixed-MPR was higher with mira-
begron (38.69 [SD: 33.75] versus antimuscarinics (25.88
[SD: 28.14]) and the proportion of adherent patients was
two-times higher with mirabegron versus antimuscarinics
(22.0% versus 11.0%, respectively). Adherence measured
using variable-MPR was similar between the two groups
(Table 3). The results of the multivariate and subgroup
analyses of MPR are described in Additional file 5, with
results displayed in Additional file 6: Tables S2, Additional
file 7: Tables S3, Additional files 8: Table S4.
Discussion
This retrospective study assessed treatment persistence
and adherence in approximately 1800 patients with OAB
in Spain, who received mirabegron or an antimuscarinic
in routine clinical practice. Greater persistence was ob-
served for mirabegron versus antimuscarinics in both
the unadjusted (all eligible patients) and adjusted (multi-
variate) analyses, including a two-times larger proportion
of persistent and adherent patients at 12 months in the
mirabegron arm (primary and secondary endpoints).
These findings were supported by the results of the sen-
sitivity analyses and the data reported in various patient
subgroups.
Overall, the results of our study add to the growing
body of real-world evidence from several other coun-
tries, which indicates mirabegron provides greater treat-
ment persistence compared with antimuscarinics in
patients with OAB [21–23, 32]; 12-month persistence
with mirabegron ranged from 33% to 39% in three of
these studies [21, 22, 32]. Recent evidence from BE-
LIEVE, a large, prospective, non-interventional study of
682 patients from eight European countries (NCT02
320773), reported that 53.8% of patients were persistent
after 12 months on-treatment with mirabegron [39]; this
was the highest 12-month persistence rate observed for
mirabegron in real-world studies to date.
Median TTD and 12-month persistence rates for all
OAB treatment reported in the current study were lower
compared with recent retrospective, observational studies
of treatment persistence with mirabegron and antimus-
carinics conducted in different countries [21, 22, 40].
However, rates of 12-month persistence observed in the
current study are comparable with some of the data re-
ported in one other retrospective analysis (18%) [11, 23],
and two systematic literature reviews of persistence in pa-
tients with OAB (12–39% and 10–25%) [12, 13]. National
issues relating to clinical practice in Spain may have
Table 1 Baseline characteristics in patients who received
prescriptions for mirabegron or antimuscarinicsa
Mirabegron
(N = 1169)
Antimuscarinics
(N = 629)
Total
(N = 1798)
Sex, N (%)
Male 532 (45.5) 245 (39.0) 777 (43.2)
Female 637 (54.5) 384 (61.0) 1021
(56.8)
Age, mean (SD) 66.31
(13.41)
66.61 (14.71) 66.42
(13.88)
Age category, N (%)
< 65 years 414 (35.4) 235 (37.4) 649 (36.1)
65–80 years 617 (52.8) 277 (44.0) 894 (49.7)
> 80 years 138 (11.8) 117 (18.6) 255 (14.2)
BMI, mean (SD) 30.15
(5.47)
29.88 (5.62) 30.06
(5.52)
BMI category, N (%)b
Underweight (< 18.5) 4 (0.5) 5 (1.3) 9 (0.8)
Normal or healthy weight
(18.5–24.9)
137 (17.3) 64 (16.2) 201 (17.0)
Overweight (25.0–29.9) 277 (35.1) 153 (38.7) 430 (36.3)
Obese (≥30.0) 372 (47.1) 173 (43.8) 545 (46.0)
Treatment status, N (%)
Treatment-naïve 750 (64.2) 539 (85.7) 1289
(71.7)
Treatment-experienced 419 (35.8) 90 (14.3) 509 (28.3)
Prior treatment with α-blockers, N (%)c
Yes 157 (13.4) 58 (9.2) 215 (12.0)
No 1012
(86.6)
571 (90.8) 1583
(88.0)
Prescriber at index date, N (%)
Gynaecologist/urologist 749 (64.1) 131 (20.8) 880 (48.9)
GP 397 (34.0) 476 (75.7) 873 (48.6)
Other 23 (2.0) 22 (3.5) 45 (2.5)
Type of care for prescribed index drug, N (%)
Primary 397 (34.0) 476 (75.7) 873 (48.6)
Secondary 23 (66.1) 22 (24.3) 45 (51.4)
BMI body mass index, GP general practitioner, SD standard deviation
aAt index date
bData based on 1185 patients (mirabegron: N = 790; antimuscarinics: N = 395)
cData based on follow-up post-index date
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contributed to lower treatment persistence compared with
some studies. For example, patients in Spain are expected
to co-pay up-to 60% of drug costs [41]; cost is specified as
one of several factors that might contribute to treatment
discontinuation in the current European Association of
Urology (EAU) guidelines for UI [9].
Two similar studies to evaluate persistence on-treatment
in adults with OAB have been conducted in Spain, which re-
ported higher rates of 12-month persistence on-treatment
with solifenacin, fesoterodine or tolterodine monotherapy
(range: 30.9–40.2%) compared with our study [34, 35]. These
differences may be attributed to several factors: first, in both
other studies, retrospective data were extracted from existing
medical records from primary healthcare centres in parts of
Catalonia and the Balearic Islands, compared with data rep-
resentative of the overall Spanish population in our study.
Second, our sensitivity analyses suggest that extending the
period used to define treatment discontinuation results in
greater persistence, and one of these other studies (Sicras--
Mainar et al., 2014) used a considerably longer period to
define treatment discontinuation (52 weeks without prescrip-
tion renewal) versus our study (30 days in the base case ana-
lysis) [34]. In the other prior Spanish study (Sicras-Mainar et
al., 2015), OAB patients between 20 and 64 years of age who
were active workers were included; therefore, it’s possible
these patients may have been healthier or had a better treat-
ment response, compared with the patient population in our
study which were selected using less-stringent criteria [35].
However, no stratification was performed to evaluate the po-
tential impact of these patient characteristics.
A high proportion of patients included in our study
(82.3%) were also overweight or obese according to BMI;
these patients may be less likely to experience symptom
improvement (and perhaps more likely to discontinue
treatment) than those with lower BMI. Weight loss has
been shown to reduce the number of UI episodes in
overweight or obese women [42, 43], and is recom-
mended by the EAU to reduce the risk of developing UI,
or improve symptoms [9]. Similar to the current study,
the mean BMI values in European patients with OAB
Fig. 2 Median time to discontinuation for mirabegron versus antimuscarinics (base-case analysis; all eligible patients [N = 1798]). *Proportion of
patients persistent at 12 months. CI, confidence intervals; HR, hazard ratio; TTD, time to discontinuation
Table 2 Impact of covariates on time to discontinuation: multivariate Cox regression analysis adjusting for baseline characteristics in
all eligible patients (N = 1798)a
Target OAB drug received Treatment status Age, years
Mirabegron
(N = 1169)b
Antimuscarinics
(N = 629)
Naïve
(N = 1289)
Experienced
(N = 509)b
45–64
(N = 649)
65–74
(N = 595)
≥75
(N = 554)b
TTD
Median, days 90 56 60 99 60 90 91
(95% CI) 90–92 30–56 60–61 92–121 56–60 68–91 90–99
HR (95% CI) – 1.52 (1.37–1.70)c 1.35 (1.20–1.53)c – 1.53 (1.35–1.74)c 1.15 (1.01–1.31)d –
ATC Anatomical Therapeutic Chemical, CI confidence intervals, GP general practitioner, HR hazard ratio, OAB overactive bladder, TTD time to discontinuation
aAt index date; HR, 95% CI and p-values generated using a stepwise Cox regression model including target OAB drug received, treatment status and age
bReference comparator
cp < 0.001
dp = 0.039 (all other comparisons non-significant)
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enrolled in phase II/III studies were also indicative of
overweight [19, 44, 45]; the impact of patients’ BMI on
persistence and adherence was not evaluated in our
study and this could perhaps be investigated in subse-
quent analyses.
In our study, the majority of patients (71.7%) were de-
fined as treatment-naïve (i.e. they had not received any
prescriptions for an OAB drug during the 12 months prior
to the index date), which may have led to different expec-
tations regarding efficacy and/or tolerability compared
with treatment-experienced patients, and perhaps
contributed to the observed low overall persistence. A
proportionally smaller number of treatment-naïve patients
were prescribed mirabegron vs antimuscarinics, and as re-
ported in our study and other studies [21, 22, 46, 47], this
may have had a positive impact on the persistence data –
although treatment persistence was significantly longer
with mirabegron versus all antimuscarinics in both the
treatment naïve and treatment experienced subgroups.
Most patients were prescribed antimuscarinics through
primary care by a GP, while the majority of patients pre-
scribed mirabegron received their prescription from a gy-
naecologist or urologist in secondary care. In the
multivariate analysis of our study, the type of prescriber
was not identified (during the stepwise selection process)
as a covariate which produced a significant impact on
TTD. However, we acknowledge there are two reports
that indicate patients prescribed OAB treatment within a
specialist setting experienced greater persistence com-
pared with internal medicine/GP departments [48, 49].
Patients’ medication-taking behaviour can be attributed to
many different factors and one of these is the nature of the
communication with their physician [50]; others include the
patient’s beliefs and values [50], expectations of treatment
[14], perception of the severity of their condition [51], and
other behavioural or societal factors [51]. To mitigate some
Fig. 3 Persistence with mirabegron compared with individual antimuscarinics: subgroup analysis. *Reference comparator; †Not evaluated due to
small sample size; ‡HRs, 95% CI and p-values generated using a Cox regression model with adjustment for age and treatment status. CI, confidence
intervals; HR, hazard ratio; NR, not reached; OAB, overactive bladder; TTD, time to discontinuation
Table 3 Summary of adherence to mirabegron compared with
antimuscarinics (all eligible patients; N = 1798)
Mirabegron
(N = 1169)
Antimuscarinics
(N = 629)
MPR-fixed
Mean (SD) 38.69 (33.75) 25.88 (28.14)
Adherenta, N (%) 257 (22.0) 69 (11.0)
MPR-variable
Mean (SD) 97.65 (4.03) 98.03 (4.57)
Adherenta, N (%) 1163 (99.5) 619 (98.4)
MPR medical possession ratio, SD standard deviation
aMPR of ≥80%
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of these factors having a negative impact on-treatment per-
sistence and adherence, it is important that the patients’
treating physician provides them with the appropriate infor-
mation/education during initial consultations, involves the
patient in decision making throughout the course of treat-
ment, and helps to manage their expectations around effi-
cacy and tolerability. Also, a wide variety of comorbidities
(including other urological conditions, neurological diseases,
endocrine disorders, respiratory dysfunctions, faecal motility
disorders, and pelvic cancer) may cause or worsen OAB
symptoms [27]. Therefore, individualised treatment for pa-
tients with OAB, taking all aspects of a patients’ condition
into account (i.e. treating OAB in the context of all comor-
bidities, rather than as a single condition) may be crucial for
improving rates of persistence and adherence.
A higher proportion of patients in the current study
(65.0%) received mirabegron compared with antimuscarinics
(35.0%). Of the 629 patients prescribed an antimuscarinic,
only trospium was prescribed to fewer than 90 patients and
this antimuscarinic was not evaluated for 12-month persist-
ence due to the small sample size (N = 18). The difference in
the number of patients who received mirabegron and anti-
muscarinics may be attributed to mirabegron first being mar-
keted in Spain in April 2014, fewer than two months prior to
the start of the selection period [16]. It is possible that the
proportional difference in prescriptions observed for mirabe-
gron versus antimuscarinics may have contributed to the
findings of our study, but this was not formally assessed.
Strengths of the study were the large sample size of ap-
proximately 1800 patients with OAB, and the collection of
real-world data from a representative sample of patients
treated in routine clinical practice in Spain. The main study
limitation was the lack of significance estimates for the pri-
mary and secondary endpoints, which were not available as
the protocol did not allow for adjustment of potential con-
founding factors in these specific analyses. However, signifi-
cantly greater persistence was observed for mirabegron
compared with antimuscarinics when Cox regression ana-
lyses were performed. Although the study tested for the con-
founding factors expected to be most important based on
previous studies (and only those which had a significant asso-
ciation with TTD were included in our Cox regression
models), the nature of retrospective database studies meant
that all important confounding factors were unlikely to be
captured, due to the analyses of limited secondary data (for
example, information on the type of OAB symptoms or their
severity were unavailable). Other limitations related to the
database included persistence and adherence measured
based on prescription data, rather than information being
directly recorded by the treating physician; plus, several fac-
tors that could potentially impact treatment persistence were
not recorded (e.g. physician compliance to management
guidelines; severity of OAB symptoms; overall health/fragility
of patients; physician bias for initial treatment/switching).
Also, the trends observed for fixed- and variable-MPR were
not consistent and might have resulted from a proxy of the
methodology used (i.e. denominators of 365 days and me-
dian TTD, respectively). Finally, persistence and adherence
estimates may not have been completely accurate, as the
study evaluated prescriptions issued, but information regard-
ing collection or correct use of the prescribed medication ac-
cording to the recommended regimen was not available;
however, this would have likely impacted all patients, inde-
pendent of the OAB treatment prescribed.
It is possible that the observed differences in persistence
and adherence for mirabegron versus antimuscarinics in
the current study, consistent with previous studies con-
ducted in Canada and the UK [21, 22], could be attributed
to an improved tolerability profile with mirabegron; in
particular, a lower incidence of bothersome anticholiner-
gic AEs such as dry mouth and constipation [20, 52].
However, as discussed above, many different factors are
involved in patients’ medication-taking behaviour. Re-
cently published data from the BELIEVE study reported
insufficient relief of symptoms, poor tolerability due to
side effects, and the cost/amount of co-pay among the
most common reasons for switching from or discontinu-
ing treatment with mirabegron [39]. Future studies, in-
cluding PERSPECTIVE (Clinicaltrials.gov: NCT02386072
[53] should offer additional insights into the underlying
differences in treatment persistence and adherence across
therapies used for OAB, possible reasons for treatment
discontinuation and the potential impact on clinical prac-
tice (e.g. for clinical outcomes, economic impact and re-
source use).
Conclusions
Mirabegron is associated with greater treatment persist-
ence and adherence in patients with OAB, compared
with antimuscarinics. The differences in mechanism of
action and efficacy/tolerability profile may contribute to
this reported treatment benefit and supports data show-
ing that mirabegron is an appropriate treatment option
for patients with OAB. The real-world evidence from
this longitudinal, observational cohort study of OAB in
Spain may provide strategic insights for clinicians and
policy makers involved in the management of patients
with this chronic condition. However, further study is
needed to understand the different factors that may con-
tribute to low persistence and adherence on-treatment
with OAB pharmacotherapy. Some of these factors may
be mitigated by the patient’s treating physician providing
them with appropriate information during initial consul-
tations, involving them in decision making throughout
the course of treatment, helping to manage their expec-
tations around efficacy and tolerability, and implement-
ing an individualised treatment strategy.
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